Literature DB >> 29032188

Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.

Thomas Gevaert1, Rodolfo Montironi2, Antonio Lopez-Beltran3, Geert Van Leenders4, Yves Allory5, Dirk De Ridder6, Frank Claessens7, Mark Kockx8, Murat Akand9, Steven Joniau6, George Netto10, Louis Libbrecht11.   

Abstract

Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. The increasing knowledge on the genomic landscape of GU cancers supports stratification of patients for targeted therapies. This review focusses on emerging biomarkers and the role of genomics in predicting clinical benefit to immunomodulatory agents in GU cancers. Based on cancer incidences and available data we restricted this overview to bladder, prostate and renal cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Bladder; Immunotherapy; Kidney; Prostate

Mesh：

Substances：

Year:  2017        PMID： 29032188     DOI： 10.1016/j.semcancer.2017.10.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  7 in total

1.  Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.

Authors:  Kevin Lu; Kun-Yuan Chiu; Chen-Li Cheng
Journal:  Cancer Treat Res       Date:  2022

Review 2.  The Identification of Immunological Biomarkers in Kidney Cancers.

Authors:  Antonio Lopez-Beltran; Vanessa Henriques; Alessia Cimadamore; Matteo Santoni; Liang Cheng; Thomas Gevaert; Ana Blanca; Francesco Massari; Marina Scarpelli; Rodolfo Montironi
Journal:  Front Oncol       Date:  2018-11-02       Impact factor: 6.244

Review 3.  Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.

Authors:  Antonio Lopez-Beltran; Alessia Cimadamore; Ana Blanca; Francesco Massari; Nuno Vau; Marina Scarpelli; Liang Cheng; Rodolfo Montironi
Journal:  Cancers (Basel)       Date:  2021-01-03       Impact factor: 6.639

Review 4.  REVIEW OF THE BLADDER CANCER MOLECULAR CLASSIFICATION PROPOSED: A NEW ERA - NEW TAXONOMY.

Authors:  Šoip Šoipi; Majda Vučić; Borislav Spajić; Božo Krušlin; Miroslav Tomić; Monika Ulamec
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.780

5.  Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection.

Authors:  Enrico Munari; Giulia Querzoli; Matteo Brunelli; Marcella Marconi; Marco Sommaggio; Marco A Cocchi; Guido Martignoni; George J Netto; Anna Caliò; Linda Quatrini; Francesca R Mariotti; Claudio Luchini; Ilaria Girolami; Albino Eccher; Diego Segala; Francesco Ciompi; Giuseppe Zamboni; Lorenzo Moretta; Giuseppe Bogina
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

6.  Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores.

Authors:  Thomas Gevaert; Yves-Rémi Van Eycke; Thomas Vanden Broeck; Hein Van Poppel; Isabelle Salmon; Sandrine Rorive; Frank Claessens; Dirk De Ridder; Christine Decaestecker; Steven Joniau
Journal:  Sci Rep       Date:  2018-09-25       Impact factor: 4.379

Review 7.  Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.

Authors:  Wout Devlies; Markus Eckstein; Alessia Cimadamore; Gaëtan Devos; Lisa Moris; Thomas Van den Broeck; Rodolfo Montironi; Steven Joniau; Frank Claessens; Thomas Gevaert
Journal:  Cells       Date:  2020-11-17       Impact factor: 6.600
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.